BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Agilent Introduces NovoCyte Opteon Spectral Flow Cytometer, Redefining Flow Cytometry Standards

Agilent has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system ...

May 06, 2024 | News

HanAll Launches Phase III VELOS-4 Trial for Tanfanercept in Dry Eye Treatment

HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Pha...

May 06, 2024 | News

ImmunityBio and Serum Institute of India Secure Global BCG Supply Agreement for Cancer Treatment

Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatme...

May 03, 2024 | News

Everest Medicines Secures NDA Approval for Nefecon® in Hong Kong, Expanding Treatment Reach in Asia

Everest Medicines announced that the Hong Kong Department of Health had approved Nefecon® for the treatment of primary immunoglobulin A nephropath...

May 02, 2024 | News

AstraZeneca Highlights Key Respiratory and Immune Research at ATS 2024

AstraZeneca will present new clinical and real-world data from its expansive respiratory portfolio at the American Thoracic Society (ATS) International Con...

May 02, 2024 | News

Infinitopes Raises £12.8M to Expand Precision Immunomics™ for Five Additional Cancers

- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen disco...

May 01, 2024 | News

AstraZeneca's ENHERTU Shows Breakthrough in Treating HR-Positive, HER2-Low Breast Cancer in Latest Trial

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statis...

April 30, 2024 | News

WuXi AppTec Reports First Quarter 2024 Financial Results: Solid Performance with Continued Growth in R&D Services

First Quarter 2024 Financial Highlights: Revenue of RMB 7,982 million, with a slight decrease of 1.8% in non-COVID-19 commercial projects, underscoring ...

April 30, 2024 | Company results

FDA Approves Ractigen Therapeutics' IND for Groundbreaking Bladder Cancer Therapy

Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration...

April 29, 2024 | News

Hyundai Bioscience Targets p53 Gene Mutations with Novel Niclosamide-Based Cancer Therapy

The only solution for intractable cancer caused by mutations in the p53 gene Planning clinical trials targeting cancer patients with no available treatm...

April 26, 2024 | News

Hyundai Bioscience Launches Clinical Trials for Innovative Niclosamide-Based Cancer Drug

Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients with difficult-to-treat cancers such as triple-negative...

April 23, 2024 | News

WuXi AppTec's Changzhou Facility Gains PMDA Approval, Bolstering Global Expansion Plans

Latest regulatory approval follows on the back of expansion plans announced during DCAT 2024 With peptides, oligos and peptide conjugates continui...

April 22, 2024 | News

GenFleet Therapeutics Secures FDA Approval for Pioneering Phase III KRAS G12C Inhibitor Trial in Colorectal Cancer

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Adm...

April 22, 2024 | News

Hyundai Bioscience to Conduct Global Clinical Trials for Groundbreaking Dengue Treatment

Hyundai Bioscience CEO Oh Sang-gi, announced its plan to launch global clinical trials for a revolutionary treatment targeting all four serotypes of ...

April 22, 2024 | News

Stay Connected